Proteome Sciences (LON:PRM) Trading Up 45.5% – Should You Buy?

Proteome Sciences plc (LON:PRM)’s stock price rose 45.5% during trading on Wednesday . The stock traded as high as GBX 2.50 and last traded at GBX 2.40. Approximately 1,057,249 shares changed hands during mid-day trading, an increase of 338% from the average daily volume of 241,283 shares. The stock had previously closed at GBX 1.65.

Proteome Sciences Stock Down 14.5%

The business’s 50 day moving average is GBX 1.90 and its 200 day moving average is GBX 2.67. The company has a debt-to-equity ratio of -258.66, a quick ratio of 0.37 and a current ratio of 0.20. The stock has a market cap of £7.07 million, a price-to-earnings ratio of -2.12 and a beta of 0.07.

Proteome Sciences (LON:PRM) last announced its quarterly earnings data on Thursday, September 25th. The company reported GBX (0.73) EPS for the quarter. Proteome Sciences had a negative return on equity of 0.01% and a negative net margin of 0.04%.

Proteome Sciences Company Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.